Blepharoplasty Market Report 2026

The blepharoplasty market size has grown strongly in recent years. It will grow from $4.54 billion in 2025 to $4.9 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing aesthetic awareness, rising aging population seeking eyelid correction, availability of skilled cosmetic surgeons, expansion of ambulatory surgical centers, growing acceptance of cosmetic procedures.

The blepharoplasty market size is expected to see strong growth in the next few years. It will grow to $6.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing adoption of advanced surgical technologies, rising demand for combined cosmetic and functional procedures, expansion of outpatient and day-care surgeries, growing focus on patient safety and recovery outcomes, increasing integration of digital surgical planning tools. Major trends in the forecast period include advancements in minimally invasive surgical techniques, growing demand for cosmetic facial procedures, rising adoption of laser-assisted surgeries, enhanced focus on functional vision correction, expansion of outpatient surgical services.

The rising prevalence of renal disease is anticipated to drive the growth of the blepharoplasty market in the coming years. Renal disease, or chronic kidney disease (CKD), is a medical condition marked by the gradual loss of kidney function. Renal disease can lead to eye puffiness and changes in eyelid positioning, and patients with renal disease should have their kidney function evaluated before undergoing blepharoplasty surgery. For example, in May 2023, the National Institutes of Health, the primary agency of the United States government responsible for biomedical and public health research, reported that around 808,000 individuals in the United States were living with end-stage renal disease (ESRD), also known as ESKD, with 69% receiving dialysis and 31% having undergone a kidney transplant. Consequently, the growing prevalence of renal disease is contributing to the expansion of the blepharoplasty market.

Key players in the blepharoplasty market are concentrating on the development of advanced technologies, such as plasma technology, to strengthen their market position. Plasma technology involves the use of ionized gases, or plasmas, in specialized medical devices to achieve non-surgical skin tightening and rejuvenation around the eyelids and other facial areas. For instance, in January 2023, Apyx Medical Corporation, a US-based advanced energy technology company, introduced the latest-generation Renuvion generator, the Apyx One Console. This multifunctional energy system is designed for plastic and cosmetic surgeries, incorporating Renuvion technology (helium plasma and radiofrequency technology) alongside monopolar and bipolar energy options. The console offers adaptive touchscreens, procedural presets, cloud connectivity, remote upgrade capabilities, gas volume monitoring, and other advanced features that enhance cosmetic surgical procedures, including eyelid surgery.

In February 2023, Athenix, a US-based medical practice company specializing in plastic surgery procedures, acquired Marina Plastic Surgery and MedSpa for an undisclosed amount. Through this strategic acquisition, Athenix aims to broaden its presence in the plastic surgery sector and strengthen its service offerings. The company also highlights its commitment to delivering comprehensive and innovative plastic surgery solutions, further positioning itself as a trusted provider in the industry. Marina Plastic Surgery and MedSpa is a US-based provider of plastic surgery services, specializing in blepharoplasty procedures.

Major companies operating in the blepharoplasty market are Zimmer Biomet Holdings Inc., Cynosure Technologies Pvt Ltd., Galderma SA, Bausch & Lomb Incorporated, Allergan Inc, Integra LifeSciences Inc., Merz Pharma GmbH & Co. KGaA, Corza Ophthalmology, Lumenis Ltd., Cutera Inc., Stille AB, Alma Lasers Ltd, Sciton Inc, Beaver-Visitec International Holdings Inc., Sklar Surgical Instruments, Hayden Medical Inc, Gulmaher Surgico, Luminera Derm Ltd, Jedmed Instrument Company, Xelpov Surgical, Surgitrac Instruments UK Limited, Surgical Holdings, Surgipro Inc., LightScalpel Inc., SPIRAL Surgical Co., Carnegie Surgical LLC., Ambler Surgical LLC.

North America was the largest region in the blepharoplasty market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blepharoplasty market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blepharoplasty market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the blepharoplasty market by increasing costs of imported surgical instruments, laser systems, medical consumables, and advanced ophthalmic devices. Hospitals and cosmetic clinics in North America and Europe are most affected due to reliance on imported surgical technologies, while Asia-Pacific faces cost pressure on device procurement. These tariffs are increasing procedure costs and capital investment requirements for clinics. However, they are also supporting domestic manufacturing of surgical tools, regional production of medical devices, and innovation in cost-efficient cosmetic surgery equipment.

The blepharoplasty market research report is one of a series of new reports that provides blepharoplasty market statistics, including blepharoplasty industry global market size, regional shares, competitors with a blepharoplasty market share, detailed blepharoplasty market segments, market trends and opportunities, and any further data you may need to thrive in the blepharoplasty industry. This blepharoplasty market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blepharoplasty is a surgical procedure that enhances the appearance of the eyelids by removing surplus skin, muscle, and fat from both the upper and lower eyelids. It is carried out for cosmetic and functional reasons to improve eye aesthetics and address vision obstruction caused by drooping eyelids.

The primary types of blepharoplasty include upper eyelid blepharoplasty, lower eyelid blepharoplasty, and combined eyelid surgery. Upper eyelid blepharoplasty involves removing excess skin, muscle, and fat from the upper eyelids to rejuvenate their appearance by eliminating extra tissue and achieving a more refreshed look. Blepharoplasty is performed on both women and men by end-users such as hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The blepharoplasty market consists of revenues earned by entities by providing transconjunctival blepharoplasty, canthoplasty, and revision blepharoplasty. The market value includes the value of related goods sold by the service provider or included within the service offering. The blepharoplasty market also includes sales of implants, eyelid cleansers and solutions, eyelid tape, and strips. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.